Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGSWW) Depreciation & Amortization (CF) (2020 - 2025)

GeneDx Holdings has reported Depreciation & Amortization (CF) over the past 6 years, most recently at $6.9 million for Q4 2025.

  • Quarterly results put Depreciation & Amortization (CF) at $6.9 million for Q4 2025, up 23.8% from a year ago — trailing twelve months through Dec 2025 was $25.2 million (up 14.9% YoY), and the annual figure for FY2025 was $25.2 million, up 14.9%.
  • Depreciation & Amortization (CF) for Q4 2025 was $6.9 million at GeneDx Holdings, up from $6.5 million in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for WGSWW hit a ceiling of $34.0 million in Q4 2022 and a floor of $4.9 million in Q1 2021.
  • Median Depreciation & Amortization (CF) over the past 5 years was $6.0 million (2023), compared with a mean of $8.1 million.
  • Biggest five-year swings in Depreciation & Amortization (CF): skyrocketed 487.4% in 2022 and later crashed 82.1% in 2023.
  • GeneDx Holdings' Depreciation & Amortization (CF) stood at $5.8 million in 2021, then skyrocketed by 487.4% to $34.0 million in 2022, then crashed by 82.1% to $6.1 million in 2023, then fell by 8.8% to $5.6 million in 2024, then increased by 23.8% to $6.9 million in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $6.9 million (Q4 2025), $6.5 million (Q3 2025), and $6.2 million (Q2 2025) per Business Quant data.